The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10651 malaria professionals are enjoying the free benefits of MalariaWorld today

artemether-lumefantrine (AL)

Efficacy and safety of artemisinin-based combination therapy and the implications of Pfkelch13 and Pfcoronin molecular markers in treatment failure in Senegal

June 2, 2020 - 14:08 -- Open Access
Author(s): 
Diallo MA, Yade MS, Ndiaye D, et al.
Reference: 
Sci Rep. 2020 Jun 1; 10(1):8907

In 2006, Senegal adopted artemisinin-based combination therapy (ACT) as first-line treatment in the management of uncomplicated malaria. This study aimed to update the status of antimalarial efficacy more than ten years after their first introduction. This was a randomized, three-arm, open-label study to evaluate the efficacy and safety of artemether-lumefantrine (AL), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP) in Senegal.

Drug Interactions between Dolutegravir and Artemether-Lumefantrine or Artesunate-Amodiaquine

February 5, 2019 - 17:54 -- Open Access
Author(s): 
Stephen I. Walimbwa, Mohammed Lamorde, Saye H. Khoo, et al.
Reference: 
Antimicrob. Agents Chemother. January 2019 63:e01310-18

Across sub-Saharan Africa, patients with HIV on antiretrovirals often get malaria and need cotreatment with artemisinin-containing therapies.

NOT Open Access | Antimalarial Resistance Unlikely To Explain U.K. Artemether-Lumefantrine Failures

June 27, 2017 - 17:58 -- NOT Open Access
Author(s): 
Rob W. van der Pluijm, James Watson, and Charles J. Woodrow
Reference: 
Antimicrob. Agents Chemother. July 2017 vol. 61 no. 7 e00721-17

No abstract available

NOT Open Access | Efficacy and safety of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria at sentinel sites in Mozambique, 2015

June 20, 2017 - 14:36 -- NOT Open Access
Author(s): 
Crizolgo Salvador, Bernardete Rafael, Sónia Enosse, et al.
Reference: 
Acta Tropica, Volume 171, July 2017, Pages 146–150

The resistance of Plasmodium falciparum to anti-malarial drugs continues to challenge malaria control.

Medical Treatment: 

Therapeutic efficacy trial of artemisinin-based combination therapy for the treatment of uncomplicated malaria and investigation of mutations in k13 propeller domain in Togo, 2012–2013

June 28, 2016 - 16:44 -- Open Access
Author(s): 
Améyo M. Dorkenoo, Degninou Yehadji, Pascal Ringwald, et al.
Reference: 
Malaria Journal 2016 15:331, 22 June 2016

The efficacy of AL and ASAQ remains high in Togo, and both drugs are well tolerated.

NOT Open Access | Risk factors for Plasmodium falciparum and Plasmodium vivax gametocyte carriage in Papua New Guinean children with uncomplicated malaria

June 1, 2016 - 14:46 -- NOT Open Access
Author(s): 
Stephan Karl, Moses Laman, Timothy M.E. Davis, et al.
Reference: 
Acta Tropica Volume 160, August 2016, Pages 1–8

There are limited data on gametocytaemia risk factors before/after treatment with artemisinin combination therapy in children from areas with transmission of multiple Plasmodium species.

Person: 
Medical Treatment: 

NOT Open Access | Tailoring a Pediatric Formulation of Artemether-Lumefantrine for Treatment of Plasmodium falciparum Malaria

July 22, 2015 - 10:15 -- NOT Open Access
Author(s): 
Quique Bassat, Bernhards Ogutu, Abdoulaye Djimde, Kirstin Stricker, and Kamal Hamed
Reference: 
Antimicrob. Agents Chemother. August 2015 vol. 59 no. 8 4366-4374

Specially created pediatric formulations have the potential to improve the acceptability, effectiveness, and accuracy of dosing of artemisinin-based combination therapy (ACT) in young children, a patient group that is inherently vulnerable to malaria.

Assessing the quality of anti-malarial drugs from Gabonese pharmacies using the MiniLab ® : a field study

July 14, 2015 - 09:34 -- Open Access
Author(s): 
Benjamin J Visser, Janneke Meerveld-Gerrits, Martin P Grobusch, et al.
Reference: 
Malaria Journal 2015, 14:273 (15 July 2015)

Using the GPHF Minilab ® , the prevalence of poor-quality anti-malarial drugs is far lower than anticipated.

Costs and cost-effectiveness of a large-scale mass testing and treatment intervention for malaria in Southern Province, Zambia

May 22, 2015 - 13:02 -- Open Access
Author(s): 
Kafula Silumbe, Joshua O Yukich, Busiku Hamainza, Adam Bennett, Duncan Earle, Mulakwa Kamuliwo, Richard W Steketee, Thomas P Eisele, John M Miller
Reference: 
Malaria Journal 2015, 14:211 (20 May 2015)

The intervention appears to be highly cost-effective relative to World Health Organization thresholds for malaria burden reduction in Zambia as compared to no MTAT

Country: 
Medical Treatment: 

Are Tanzanian patients attending public facilities or private retailers more likely to adhere to artemisinin-based combination therapy?

March 2, 2015 - 18:43 -- Open Access
Author(s): 
Katia Bruxvoort, Admirabilis Kalolella, Matthew Cairns, Charles Festo, Mitya Kenani, Peter Lyaruu, S Kachur, David Schellenberg, Catherine Goodman
Reference: 
Malaria Journal 2015, 14:87 (19 February 2015)

When controlling for patient characteristics, there was some evidence that the adjusted odds of adherence for ADDO patients was lower than that for public health facility patients.

Pages

Subscribe to RSS - artemether-lumefantrine (AL)